Regeneron Pharmaceuticals Announces Failed Phase 3 Melanoma Trial for Fianlimab Combination Therapy
Regeneron Pharmaceuticals (REGN) shares dropped over 10% after its experimental melanoma therapy combination failed to meet primary endpoints in a late-stage trial. The failure removes an anticipated revenue driver, leading RBC analysts to cut their price target and raise concerns about near-term bearish momentum.
Topics: biotech immunotherapy melanoma pharmaceuticals stock_impact